CSTL
Castle Biosciences IncKey Statistics
About Castle Biosciences Inc
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Fundamentals
| Revenue (TTM) | $344.23M |
| Gross Profit (TTM) | $273.20M |
| EBITDA | $-2.04M |
| Operating Margin | -4.40% |
| Return on Equity | -5.21% |
| Return on Assets | -2.56% |
| Revenue/Share (TTM) | $11.88 |
| Book Value | $15.86 |
| Price-to-Book | 1.61 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 1.436 |
| EV/EBITDA | 43.57 |
| Quarterly Earnings Growth (YoY) | -51.60% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $30.30M |
| Float | $25.26M |
| % Insiders | 2.38% |
| % Institutions | 91.21% |
Historical Volatility
Volatility is currently expanding